Team

People with deep sector expertise and a shared commitment to value creation.

Our team combines investment, operational and scientific experience to support companies and investors through critical moments of growth and transition.

Management team

Partners.

Portrait of Dr. David Karabelnik

Dr. David Karabelnik

Founder & CEO · Zurich

Entrepreneur and corporate finance specialist in life sciences and pharma. Founder and CEO of Breslin AG; previously founder of Breslin Biotech AG, a life sciences venture firm launched with Dresdner-Allianz. He has held six board seats, including GPC Biotech and 4SC, advised and invested for Deutsche Bank and Commerzbank, and led two companies through IPOs. Co-founder of Anawa Laboratories, later acquired by MDS Pharma Services. PhD in biochemistry, ETH Zurich.

Portrait of Dr. Detlef Wollweber

Dr. Detlef Wollweber

Life Sciences · Pharma · Agro

With Breslin since 2013. Former CEO of Bayer Innovation GmbH and Bayer Innovation Ventures, with advisory roles at Bayer Pharma, Bayer CropScience and Fraunhofer ISC. Earlier head of research at Bayer CropScience. PhD in organic chemistry, Ruhr University Bochum; named on more than 30 patents; lectured at the University of Düsseldorf for over a decade.

Portrait of Klaus Berding

Klaus Berding

Corporate Finance · Life Sciences & Technology

More than 25 years in banking and consulting. Part of Breslin’s operating team since 2005; since 2003 he has led his own corporate finance firm, LSFA. Earlier SVP and Director at Dresdner Kleinwort in the Chemicals and Healthcare group, where he helped expand the bank’s international equity and IPO business across more than 40 transactions. Co-founder and board member of Amypopharma. MBA, Ruhr University Bochum; DVFA postgraduate degree.

Portrait of Dr. Martin Schnee

Dr. Martin Schnee

Financial Analysis · Chemistry & Biotech

Associated partner since 2010 and founder of Schnee Research, working with AlphaValue, Europe’s largest independent research house. Earlier analyst roles at Commerzbank covering biotech, pharma, medtech and chemicals. PhD in chemistry, Goethe University Frankfurt; certified credit and biotech equity analyst; member of DVFA, GDCh and CLIB; non executive director at a German gene therapy company.

Portrait of Dr. Francis Chen

Dr. Francis Chen

Life Sciences & Venture Capital · San Francisco

Board member since 2006 of Mighty Therapeutics (formerly Stealth BioTherapeutics), developer of the first FDA-approved therapy for Barth syndrome. Former Vice Chairman of WI Harper Group, a venture firm active in Silicon Valley and Greater China. Over 20 years in healthcare management at Becton Dickinson and Baxter. PhD in immunology, Harvard University; MS and BS in chemistry, Tufts University.

Portrait of Nathan Breslin

Nathan Breslin

Strategic Development & Fundraising · Zurich

Finance and legal specialist in transactions, investment strategy and corporate growth. Supports buy side secondaries and manages the strategic and financial aspects of transactions, including contract negotiation and growth planning.

Advisory team

Sector advisors.

David Toledo

Private & Public Equity · Zurich

Finance and legal professional in private equity transactions, investment strategy and corporate advisory: due diligence, valuation, fundraising and secondaries, with end to end execution.

Dr. Herve de Kergrohen

Life Sciences & Investment Banking · Lausanne

More than 25 years in life sciences and asset management. Fund manager at CDC Innovation and BB Medtech among others, founder of several European biotech companies and of the Biodata conference in Geneva. Medical degree; MBA, INSEAD.

Dr. Manfred Kircher

Industrial Biotech & Speciality Chemicals · Düsseldorf

More than 25 years in senior roles at Evonik and Degussa. Former chairman of CLIB 2021, the international industrial biotech association, and portfolio manager for the Burrill Nutraceutical Fund. PhD in molecular genetics.

Christoph Kayenburg

Private & Public Equity · Munich

Specialist in commercial and investment banking, including five years at DG Bank in Tokyo and capital markets work in South Korea and London. Chairman of Krayenburg AG, Munich. Master in economics.

Dr. Jakob Karp

Medical Technology · Munich

Twenty years developing tools, systems and methods for orthodontic and medtech applications, alongside teaching and market communication for the dental and medtech markets. PhD in orthodontics.

Speak with the partner closest to your question.

Enquiries reach the team directly. There is no client services layer in between.

Contact us
Scroll to Top